All In Biotech

Drug Trial Radar · NCT04923347

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety and Efficacy of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in Participants With Chronic Obstructive Pulmonary Disease in India

Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

229

Actual

Start

Jun 6, 2023

Primary completion

Mar 14, 2024

Study completion Mar 14, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • FF/UMEC/VIDrug

    FF/UMEC/VI will be administered

  • ELLIPTADevice

    Participants will receive FF/UMEC/VI using ELLIPTA inhaler.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Adverse Events of Special Interest (AESIs)Time frame: Up to approximately 40 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ajmer, India

  • GSK Investigational Site

    Bangalore, India

  • GSK Investigational Site

    Bikaner, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Jaipur, India

  • GSK Investigational Site

    Kolkata, India

  • GSK Investigational Site

    Kolkata, India

  • GSK Investigational Site

    Kozhikode, India

  • GSK Investigational Site

    Mumbai, India

  • GSK Investigational Site

    Mysore, India

  • GSK Investigational Site

    Nagpur, India

  • GSK Investigational Site

    Nashik, India

  • GSK Investigational Site

    Pondy-Cuddalore ECR Main Road Pillaiyarkuppam Pond, India

  • GSK Investigational Site

    Pune, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.